Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Real-time Estimate Cboe Europe  -  03:12 2022-08-16 am EDT
319.40 CHF   +0.47%
01:21aSwiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
01:02aFDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
BU
01:01aFDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ovarian Cancer Drugs

06/20/2022 | 05:10am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.08% 3865 Delayed Quote.3.56%
ROCHE HOLDING AG 0.92% 317.9 Delayed Quote.-16.14%
All news about ROCHE HOLDING AG
01:21aSwiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
01:02aFDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combinati..
BU
01:01aFDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
GL
08/15Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
RE
08/15Roche Unveils New Diagnostic Test for COVID-19 Immune Response
MT
08/15Roche launches new diagnostic test for the better understanding of immune response to S..
GL
08/15Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to S..
CI
08/14Switzerland Negotiating Pharmaceutical Trade Deal With US
MT
08/13U.S. and Switzerland working on facilitating pharma trade - U.S. ambassador
RE
08/12European shares rise as healthcare, leisure stocks gain
RE
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 249 M 67 994 M 67 994 M
Net income 2022 14 824 M 15 688 M 15 688 M
Net Debt 2022 10 272 M 10 870 M 10 870 M
P/E ratio 2022 17,1x
Yield 2022 3,04%
Capitalization 262 B 278 B 278 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,12x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 317,90 CHF
Average target price 374,13 CHF
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.14%277 502
JOHNSON & JOHNSON-2.91%434 603
ELI LILLY AND COMPANY13.66%292 730
PFIZER, INC.-15.75%281 235
ABBVIE INC.5.09%252 131
NOVO NORDISK A/S4.76%240 550